Navigation Links
Sirtris' review of sirtuin therapeutics for diseases of aging in Nature Reviews Drug Discovery
Date:10/1/2008

CAMBRIDGE, MA [October 1, 2008] Sirtris, a GSK company focused on discovering and developing small molecule drugs to treat diseases of aging such as Type 2 Diabetes, announced today that it published a new review article on the growing body of sirtuin research and its potential to treat diseases of aging such as Type 2 Diabetes, mitochondrial disorders, inflammation, cancer, and heart disease. Entitled "SIRTUINS Novel Therapeutic Targets to Treat Age-Associated Diseases," the review appears in today's issue of the journal Nature Reviews Drug Discovery.

Sirtuins are a family of enzymes which target genes that control aging. There are a total of seven sirtuin enzymes that exist in mammals. SIRT1 is the founding member of this class of enzymes and is currently the most studied of the group. When activated, SIRT1 appears to mimic some of the positive health effects seen in calorie-restricted animals.

"We are excited to be at the forefront of this research, which continues to intensify as we see positive results from early human clinical studies," said Christoph Westphal, M.D., Ph.D., Chief Executive Officer of Sirtris, a GSK company. "The body of clinical data supporting the role of SIRT1 activation as a viable mechanism for treating a broad range of diseases of metabolism and aging is growing."

Peter Elliott, Ph.D., Senior Vice President of Development, said, "At Sirtris, we are targeting the genes which control the aging process with the potential to treat diseases of aging such as diabetes, neurodegeneration, cancer, and inflammation."

This review highlights the molecular mechanism of action of sirtuins with a view towards diseases where SIRT1 activation shows therapeutic promise. Such diseases of aging include Type 2 Diabetes and mitochondrial disorders, cardiovascular disease, cancer, neurodegeneration and inflammatory diseases. One of the first small molecules discovered to exhibit the positive effects of calorie restriction is resveratrol, a natural ingredient found in red wine. Since then, Sirtris has developed its own proprietary formulation of resveratrol, SRT501. Early clinical studies in patients with Type 2 Diabetes indicate that SRT501 may lower glucose and improve insulin sensitivity. Sirtris also has new chemical entities (NCEs) which are structurally unrelated to and one-thousand times more potent than resveratrol. Sirtris' first new chemical entity is currently being evaluated for safety and tolerability in a Phase 1a study in humans.

"We are beginning to understand more about activation of other enzymes in the sirtuin family, SIRT2-7, and we're encouraged by early data that indicates a role for other sirtuins in multiple therapeutic areas," continued Dr. Westphal.


'/>"/>

Contact: Caton Lovett
caton@purecommunicationsinc.com
910-509-3975
Pure Communications Inc.
Source:Eurekalert

Related biology news :

1. Sirtris unveils promising, novel SIRT1 activators for treating diseases of aging
2. Review article provides tools for the Rosaceae genomics community
3. Medicines derived from cannabis: a review of adverse events
4. Stanford researchers publish review of US medical device regulation
5. Media invitation: 20th EORTC-NCI-ACR Symposium on Molecular Targets and Cancer Therapeutics
6. CU-Boulder, biotech firm team up on python project in search for human cardiac therapeutics
7. Michael J. Fox Foundation PD Therapeutics Conference
8. Galapagos and Cystic Fibrosis Foundation Therapeutics announce drug discovery collaboration
9. Iron-moving malfunction may underlie neurodegenerative diseases, aging
10. Gaining a better understanding of kidney diseases
11. Biodegradable polymers show promise for improving treatment of acute inflammatory diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/6/2017)... LONDON , April 6, 2017 ... Control, RFID, ANPR, Document Readers, by End-Use (Transportation & ... Energy Facility, Oil, Gas & Fossil Generation Facility, Nuclear ... Healthcare, Educational, Other) Are you looking for ... Authentication sector? ...
(Date:4/4/2017)... , April 4, 2017   EyeLock LLC ... announced that the United States Patent and Trademark Office ... broadly covers the linking of an iris image with ... transaction) and represents the company,s 45 th issued ... patent is very timely given the multi-modal biometric capabilities ...
(Date:3/30/2017)... , March 30, 2017 Trends, opportunities and ... and behavioral), by technology (fingerprint, AFIS, iris recognition, facial ... and others), by end use industry (government and law ... financial and banking, and others), and by region ( ... , Asia Pacific , and the ...
Breaking Biology News(10 mins):
(Date:5/18/2017)... ... 17, 2017 , ... G-CON Manufacturing, Inc., the leader in ... Jornitz, was recognized as a Top 10 Industry Influencer on The Medicine Maker’s ... bettering the pharma industry and bringing life-changing medicines to market” across four categories. ...
(Date:5/18/2017)... (PRWEB) , ... May 18, 2017 , ... When James Sherley, was notified earlier this ... Most Valuable Brands for the Year 2017 by The Silicon Review , he was ... making good progress increasing Asymmetrex’s value, but this recognition by Silicon Valley was particularly meaningful. ...
(Date:5/16/2017)... ... May 16, 2017 , ... ... Hi-C metagenomic deconvolution service. ProxiMeta enables researchers to obtain complete, distinct genomes ... insights at lower cost. , “We’re very excited about the commercial launch ...
(Date:5/16/2017)... ... May 16, 2017 , ... ... diagnostics, has released its ClearID Lung Cancer blood test. Leveraging a highly-sensitive next-generation ... new test is designed to quickly and accurately identify tumor-related genetic mutations that ...
Breaking Biology Technology: